Recent Advances in Endocrinology Pathology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 1370

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
2. Department of Endocrinology, C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania
Interests: thyroid; adrenal; pituitary; osteoporosis; neuroendocrine tumors; bone; fracture; gynecological endocrinology; diabetes
Special Issues, Collections and Topics in MDPI journals
1. Department of Endocrinology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
2. Department of Endocrinology, County Emergency Clinical Hospital, 400347 Cluj-Napoca, Romania
Interests: endocrine tumors; osteoporosis; thyroid disease; parathyroid; acromegaly; cushing syndrome; insulin resistance; endocrine ultrasound

E-Mail Website
Guest Editor
1. Department 4—Cardio-Thoracic Pathology, Thoracic Surgery II Discipline, Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2. Thoracic Surgery Department, “Dr. Carol Davila” Central Emergency University Military Hospital, 013058 Bucharest, Romania
Interests: thyroid surgery; parathyroid surgery; lung neuroendocrine tumors; lung cancer; minimally invasive surgery; VATS; cervico-mediastinal surgery; thoracic-abdominal surgery; pleuro-pericardial disease; chest wall tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endocrine conditions display a heterogeneous spectrum of clinical aspects, from diagnosis to practical management. We invite you to contribute one or more articles for this Special Issue in the field of endocrine pathology.

We are particularly interested (but are open to other proposals) in the latest research, guideline updates, current controversies, and unsolved issues, including recent conceptual changes, regarding the following:

  1. Fine-needle aspiration of thyroid nodules, parathyroid masses, and neck lymph nodes;
  2. The potential gap between pre-operative assessments and post-thyroidectomy results;
  3. Single and multi-glandular parathyroid disease, parathyromatosis;
  4. Unusual ectopic locations of the endocrine glands;
  5. Thyroid malignancy and autoimmune thyroid disease: new molecular markers;
  6. Parathyroid and bone disease in chronic renal failure;
  7. Multi-organ, including new markers, in diabetic bone disease;
  8. Novel genetic and molecular testing in radioiodine-refractory thyroid cancer;
  9. Multi-modal decision in advanced, metastatic thyroid malignancies and surgery candidates;
  10. Landscape of clinical and pathological insights amid functioning or non-functioning endocrine tumors.

Dr. Mara Carsote
Dr. Ana Valea
Dr. Claudiu Nistor
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • histological classification and reporting
  • cytological analysis
  • fine-needle aspiration
  • molecular markers
  • immunohistochemistry
  • hormone
  • dynamic hormonal testing
  • endocrine tumors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 807 KB  
Article
Gonadal Dysfunction in Wolfram Syndrome: A Prospective Study
by Gema Esteban-Bueno and Juan Luis Fernández-Martínez
Diagnostics 2025, 15(13), 1594; https://doi.org/10.3390/diagnostics15131594 - 24 Jun 2025
Cited by 1 | Viewed by 877
Abstract
Background: Wolfram syndrome (WFS), also known as DIDMOAD, is a rare monogenic neurodegenerative disorder characterized by four key components: non-autoimmune insulin-dependent diabetes mellitus (DM), optic atrophy, sensorineural hearing loss, and diabetes insipidus. Although it significantly affects quality of life, gonadal dysfunction, particularly hypogonadism, [...] Read more.
Background: Wolfram syndrome (WFS), also known as DIDMOAD, is a rare monogenic neurodegenerative disorder characterized by four key components: non-autoimmune insulin-dependent diabetes mellitus (DM), optic atrophy, sensorineural hearing loss, and diabetes insipidus. Although it significantly affects quality of life, gonadal dysfunction, particularly hypogonadism, remains underrecognized. Methods: In total, 45 patients (25 men, 20 women) with genetically confirmed WFS from a single tertiary-care center were prospectively followed to assess gonadal function. Men underwent hormonal evaluations, semen analysis, imaging tests, and testicular biopsies. In women, data on age at menarche, menstrual irregularities, and age at menopause were recorded. Hormonal analyses, including anti-Müllerian hormone (AMH) levels, and imaging tests were also conducted. Results: Hypogonadism was identified in 19 men (76.0%), of whom 17 (68.0%) had hypergonadotropic hypogonadism and 2 (8.0%) had hypogonadotropic hypogonadism. Testicular biopsies showed seminiferous tubule damage, Sertoli cell predominance, and reduced Leydig cells. Azoospermia was observed in 12 patients, whereas others presented with oligozoospermia, teratozoospermia, or asthenozoospermia. Most patients exhibited low testosterone levels along with elevated LH and FSH, suggesting primary testicular failure, except for two cases of hypogonadotropic hypogonadism. Correlations between biomarkers, onset age and severity have been analyzed and provide important insights regarding medical treatment. In women, menstrual irregularities were universal, with 20% experiencing premature menopause. Four patients had low AMH levels, with ovarian atrophy in three and a postmenopausal uterus in two, indicating early hypogonadism risk. Conclusions: Gonadal dysfunction is a significant yet overlooked feature of WFS, requiring systematic evaluation during puberty and beyond. Proper management is essential to mitigate metabolic disturbances and psychological impacts, including infertility distress, relationship challenges, and quality of life concerns. Addressing sexual health is crucial as WFS patients live longer and aspire to establish relationships or start families. Full article
(This article belongs to the Special Issue Recent Advances in Endocrinology Pathology)
Show Figures

Graphical abstract

Other

Jump to: Research

11 pages, 2816 KB  
Interesting Images
Hematological Malignancy in a Hypophysectomised Acromegalic Patient Under 4-Year Therapy with Somatostatin Analogues: From a Rib Lump Underlying Bone Plasmatocytoma Features to Multiple Myeloma
by Mihaela Stanciu, Alina Cătană, Ruxandra Paula Ristea, Denisa Tanasescu, Mara Carsote, Florina Ligia Popa and Ioana-Codruța Lebădă
Diagnostics 2025, 15(20), 2623; https://doi.org/10.3390/diagnostics15202623 - 17 Oct 2025
Viewed by 237
Abstract
Acromegaly is associated with a higher risk of certain malignancies, but not hematological neoplasia, although multiple myeloma (MM) was found in very limited cases. We aim to present such a case, adding a particular presentation with co-occurrence of a plasmocytoma. A 52-year-old male [...] Read more.
Acromegaly is associated with a higher risk of certain malignancies, but not hematological neoplasia, although multiple myeloma (MM) was found in very limited cases. We aim to present such a case, adding a particular presentation with co-occurrence of a plasmocytoma. A 52-year-old male with acromegaly confirmed at 46 (MRI: pituitary macroadenoma of 12 × 11 × 10 mm) underwent hypophysectomy followed by 3 years of octreotide LAR then lanreotide depot. After another 6 months, he experienced a rapidly growing, painful lump in the right lateral thoracic area confirmed by CT as a 9-cm osteolytic lesion at the third rib. Core biopsy revealed plasmocytoma of the bone and medullary biopsy confirmed MM. Plasmacytoma was managed with 10 radiotherapy sessions, with favorable outcome and mass resorption; MM was managed with a VRD regimen, followed by autologous hematopoietic stem-cell transplantation. Six months after sFLC normalization and plasmacytoma resorption, complete remission was reported. In the meantime, lanreotide was continued, with complete acromegaly control. To conclude, what started as a rather typical scenario for an otherwise rare condition, as is acromegaly in the general population (but not so rare for endocrinologists), turned into an unexpected and more severe outcome. Noting this exceptional association, we pinpoint that further research is needed for understanding the dual acromegaly–MM relationship. Full article
(This article belongs to the Special Issue Recent Advances in Endocrinology Pathology)
Show Figures

Figure 1

Back to TopTop